文献速递临床试验与 GCP真实世界研究与卫生经济

飞秒激光辅助与超声乳化白内障手术(FEMCAT):多中心参与者设盲随机优效性与成本效果试验

Femtosecond laser-assisted versus phacoemulsification cataract surgery (FEMCAT): a multicentre participant-masked randomised superiority and cost-effectiveness trial.
PubMed 文献 · Lancet · 2020-01-01

在5家法国大学医院纳入907例(1476眼)白内障手术患者,随机比较飞秒激光辅助(FLACS)与超声乳化(PCS)。FLACS未显示优效且成本更高。

要点

  • 飞秒激光步骤未观察到严重不良事件,FLACS组主要结局相关并发症多发生于超声乳化或术后。

核心结论

  • 飞秒激光辅助并未优于超声乳化白内障手术,且成本更高,未为患者或医疗系统提供额外获益。

研究设计与样本

  • 多中心参与者设盲随机优效性临床试验,5家法国大学医院纳入≥22岁适合单眼或双眼白内障手术的连续患者。
  • 907例(1476眼)随机分组,870例(FLACS组704眼、PCS组685眼)纳入分析,缺失数据视为失败。
  • 随机分组按中心分层、1:1分配,PCS组设置假激光程序,参与者、结局评估者和检查技师设盲至末次随访。

主要发现

  • 飞秒激光步骤未观察到严重不良事件,FLACS组主要结局相关并发症多发生于超声乳化阶段或术后。

关键数值与推荐

  • 主要经济终点为3个月时每多1例治疗成功的增量成本。

临床怎么用

  • 在常规白内障手术中,飞秒激光辅助未显示比超声乳化更高的手术成功率,且成本更高,决策时应考虑成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cataract surgery is one of the most common operations in health care. Femtosecond laser-assisted cataract surgery (FLACS) enables more precise ocular incisions and lens fragmentation than does phacoemulsification cataract surgery (PCS). We hypothesised that FLACS might improve outcomes in cataract surgery compared with PCS despite having higher costs. METHODS: We did a participant-masked randomised superiority clinical trial comparing FLACS and PCS in two parallel groups (permuted block randomisation stratified on centres via a centralised web-based application, allocation ratio 1:1, block size of 2 or 4 for unilateral cases and 2 or 6 for bilateral cases). Five French University Hospitals enrolled consecutive patients aged 22 years or older who were eligible for unilateral or bilateral cataract surgery. Participants, outcome assessors, and technicians carrying out examinations were masked to the surgical treatment allocation until the last follow-up visit and a sham laser procedure was set up for participants randomly assigned to the PCS arm. The primary clinical endpoint was the success rate of surgery, defined as a composite of four outcomes at a 3-month postoperative visit: absence of severe perioperative complication, a best-corrected visual acuity (BCVA) of 0·0 LogMAR (logarithm of the minimum angle of resolution) or better, an absolute refractive error of 0·75 dioptres or less, and unchanged postoperative corneal astigmatism power (≤0·5 dioptres) and axis (≤20°). The primary economic endpoint was the incremental cost per additional patient who had treatment success at 3 months. Primary outcomes were assessed in all randomly assigned patients who met all eligibility criteria (missing data considered as failure). We used mixed logistic regression models or mixed linear regression models for statistical comparisons, adjusted on centres and whether cataract surgery was bilateral or unilateral. The study is registered with ClinicalTrials.gov, NCT01982006. FINDINGS: Of the 907 patients (1476 eyes) randomly assigned between Oct 9, 2013, and Oct 30, 2015, 870 (704 eyes in FLACS group and 685 eyes in the PCS group) were analysed. We identified no significant difference in the success rate of surgery between the FLACS and PCS groups (FLACS: 41·1% [289 eyes]; PCS: 43·6% [299 eyes]); adjusted odds ratio 0·85, 95% CI 0·64-1·12, p=0·250). The incremental cost-effectiveness ratio was €10 703 saved per additional patient who had treatment success with PCS compared with FLACS. We observed no severe adverse events during the femtosecond laser procedure, and most of the complications in the FLACS group related to the primary outcome measures occurred during the phacoemulsification phase or postoperatively. INTERPRETATION: Despite its advanced technology, femtosecond laser was not superior to phacoemulsification in cataract surgery and, with higher costs, did not provide an additional benefit over phacoemulsification for patients or health-care systems. FUNDING: French Ministry of Social Affairs and Health.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Schweitzer C, Brezin A, Cochener B, et al. Femtosecond laser-assisted versus phacoemulsification cataract surgery (FEMCAT): a multicentre participant-masked randomised superiority and cost-effectiveness trial. Lancet. 2020. PMID: 31954466. doi:10.1016/S0140-6736(19)32481-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。